



COPY

Form P-1449 PATENT & TRADEMARK OFFICE	1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 4143	SERIAL NO. 09/748,739
		APPLICANT: Lockridge and Watkins	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: December 26, 2000	GROUP: Unknown 1639

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
ML	5,264,563	11/23/1993	Huse	536	25.3	12/14/92
ML	5,830,721	11/03/1998	Stemmer et al.	435	172.1	2/17/95

FOREIGN PATENT DOCUMENTS


EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

ML	Abremski et al., "Studies on the properties of P1 site-specific recombination: evidence for topologically unlinked products following recombination," <u>Cell</u> 32:1301-1311 (1983)
ML	Bethke and Sauer, "Segmental genomic replacement by Cre-mediated recombination: genotoxic stress activation of the p53 promoter in single-copy transformants," <u>Nuc. Acids Res.</u> 25:2828-2834 (1997)
ML	Blong et al., "Tetramerization domain of human butyrylcholinesterase is at the C-terminus," <u>Biochem. J.</u> 327:747-757 (1997)
ML	Crameri et al., "DNA shuffling of a family of genes from diverse species accelerates directed evolution," <u>Nature</u> 391:288-291 (1998)
ML	Dymecki, "Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 93:6191-6196 (1996)

EXAMINER B. Celsa	DATE CONSIDERED 1/29/03
----------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 4143	SERIAL NO. 09/748,739
	APPLICANT: Lockridge and Watkins	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 26, 2000	GROUP: Unknown 1639

ML		Fukushige and Sauer, "Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells," <u>Proc. Natl. Acad. Sci. USA</u> 89:7905-7909 (1992)
PK		Glaser et al., "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," <u>J. Immunology</u> 149:3903-3913 (1992)
ML		Gorelick, "Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy," <u>Drug Alcohol Depend.</u> 48:159-165 (1997).
PK		Harel et al., "Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis," <u>Proc. Nat. Acad. Sci. USA</u> 89: 10827-10831 (1992)
CL		Hoess et al., "The role of the loxP spacer region in P1 site-specific recombination," <u>Nucleic Acids Res.</u> 14:2287-2300 (1986)
CL		Kunkel, "Rapid and efficient site-specific mutagenesis without phenotypic selection," <u>Proc. Natl. Acad. Sci. USA</u> 82:488-492 (1985)
ML		Lockridge et al., "A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase," <u>Biochemistry</u> 36:786-795 (1997)
ML		Masson et al., "Role of aspartate 70 and tryptophan 82 in binding of succinylthiocholine to human butyrylcholinesterase," <u>Biochemistry</u> 36:2266-2277 (1997)
ML		Sauer and Henderson, "Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1," <u>Proc. Natl. Acad. Sci. USA</u> 85:5166-5170 (1988)
ML		Schwarz et al., "Engineering of human cholinesterase explains and predicts diverse consequences of administration of various drugs and poisons," <u>Pharmac. Ther.</u> 67: 283-322 (1992)

EXAMINER B. celsa	DATE CONSIDERED 11/29/03
----------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 4143	SERIAL NO. 09/748,739
	APPLICANT: Lockridge and Watkins	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 26, 2000	GROUP: 1639 Unknown

<i>MC</i>		Soreq et al., "Excavations into the active-site gorge of cholinesterases," <u>Trends Biochem. Sci.</u> 17:353-358 (1992)
<i>MA</i>		Stemmer, "DNA shuffling by random fragmentation and reassembly: <i>in vitro</i> recombination for molecular evolution," <u>Proc. Natl. Acad. Sci. USA</u> 91:10747-10751 (1994)
<i>MA</i>		Sussman et al., "Atomic structure of acetylcholinesterase from <i>Torpedo californica</i> : a prototypic acetylcholine-binding protein," <u>Science</u> 253:872-879 (1991)
<i>MA</i>		Tatusova and Madden, "BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences," <u>FEMS Microbiol Lett.</u> 174:247-250 (1999)
<i>MA</i>		Watkins et al., "Determination of the relative affinities of antibody fragments expressed in <i>Escherichia coli</i> by enzyme-linked immunosorbent assay," <u>Anal. Biochem.</u> 253: 37-45 (1997)
<i>MA</i>		Wu et al., "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues," <u>J. Mol. Biol.</u> 294:151-162 (1999)
<i>MA</i>		Wu et al., "Stepwise <i>in vitro</i> affinity maturation of Vitaxin, an $\alpha\beta_3$ -specific humanized mAb," <u>Proc. Natl. Acad. Sci. USA</u> 95:6037-6042 (1998)
<i>MA</i>		Xie et al., "An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient," <u>Molecular Pharmacology</u> 55:83-91 (1999)

EXAMINER B. CULSA	DATE CONSIDERED 1129603
----------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.